8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   ----------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): September 2, 2005

                               Immunomedics, Inc.
             ------------------------------------------------------
             (Exact Name of Registrant as Specified in Its Charter)

            Delaware                    000-12104              61-1009366
  ----------------------------         ------------       -------------------
  (State or Other Jurisdiction         (Commission         (I.R.S.  Employer
        of Incorporation)              File Number)       Identification No.)


     300 American Road, Morris Plains, New Jersey                 07950
     --------------------------------------------              ----------
       (Address of Principal Executive Offices)                (Zip Code)

       Registrant's telephone number, including area code: (973) 605-8200

                                 Not Applicable
          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 8.01.   OTHER EVENT

     On September 2, 2005, Immunomedics, Inc., a Delaware corporation (the
"Company"), received notification from The Nasdaq Stock Market ("Nasdaq")
informing the Company that the Nasdaq Listing and Qualification Panel has
determined that the Company will continue to be listed on The NASDAQ Stock
Market. On September 6, 2005, the Company issued a press release to announce its
receipt of this notification from the NASDAQ. A copy of the press release is
attached hereto as Exhibit 99.1.

ITEM 9.01.   FINANCIAL STATEMENTS AND EXHIBITS.

      (c)    Exhibits:

             99.1     Press release dated September 6, 2005, titled
                      "Immunomedics Announces Positive Ruling from Nasdaq
                      Appeal Panel."

                                       -2-


                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

Date:  September 6, 2005               IMMUNOMEDICS, INC.


                                       By: /s/ Cynthia L. Sullivan
                                           -------------------------------------
                                           Cynthia L. Sullivan
                                           President and Chief Executive Officer

                                       -3-

EX-99.1

                                                                    Exhibit 99.1

MORRIS PLAINS, N.J., Sept. 6 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU), a leading biopharmaceutical company focused on developing
monoclonal antibodies, announced today that it has received a letter from The
Nasdaq Stock Market notifying the Company that the Nasdaq Listing and
Qualification Panel has ruled in favor of the Company. As a result, the Company
will remain listed on the Nasdaq National Market.

"We are pleased with the positive ruling from the Nasdaq panel. Our stock has
been listed on The Nasdaq Stock Market for over 20 years and we look forward to
continue working with Nasdaq," commented Cynthia L. Sullivan, President and
Chief Executive Officer of the Company.

The letter from Nasdaq is related to the Nasdaq Listing Qualification Staff's
decision on June 10, 2005, to delist the Company. The Nasdaq listing staff
indicated that the Company's financing in April, 2005, did not comply with one
of the Nasdaq Marketplace Rules, which provides that stockholders must approve
an issuance of securities equal to 20% of the common stock for less than the
greater of book or market value of the stock outstanding.

The Company appeared before the Nasdaq Listing and Qualification Panel on July
21, 2005, to appeal the Nasdaq listing qualification staff's June 10th decision.
On August 19, 2005, a significant majority of the Company's stockholders
approved the two proposals presented at a special meeting thereby authorizing
the Company to file an amendment to the Company's certificate of incorporation
to increase the authorized common stock by 40 million shares, and issue common
stock upon the conversion of the Company's outstanding 5% Senior Convertible
Notes due 2008 and exercise of related Common Stock Warrants in connection with
the April 29, 2005 financing. As with all decisions made by the Nasdaq Listing
and Qualifications Panel, the Company is aware that the Nasdaq Listing and
Hearing Review Council may, on its own motion, determine to review any panel
decision within 45 calendar days after the issuance of the written decision. If
the Listing Council determines to review the decision, it may affirm, modify,
reverse, dismiss, or remand the decision to the Panel. The Company will be
immediately notified if the Listing Council determines that this matter will be
called for review.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company focused on the
development of monoclonal, antibody-based products for the targeted treatment of
cancer, autoimmune and other serious diseases. We have developed a number of
advanced proprietary technologies that allow us to create humanized antibodies
that can be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics or toxins, in each case to create highly
targeted agents. Using these technologies, we have built a pipeline of
therapeutic product candidates that utilize several different mechanisms of
action. Our lead product candidate, epratuzumab, is currently in two pivotal
Phase III trials for the treatment of patients with moderate and severe lupus
(ALLEVIATE A and B). At present, there is no cure for lupus and no new lupus
treatment drug has been approved in the U.S. in the last 40 years. We believe
that our portfolio of intellectual property, which includes approximately 90
patents issued in the United States, and more than 250 other issued patents
worldwide, protects our product candidates and technologies. Visit our web site
at http://www.immunomedics.com.



This release, in addition to historical information, may contain forward-
looking statements made pursuant to the Private Securities Litigation Reform Act
of 1995. Such statements, including statements regarding clinical trials,
out-licensing arrangements, and capital raising activities, involve significant
risks and uncertainties and actual results could differ materially from those
expressed or implied herein. Factors that could cause such differences include,
but are not limited to, risks associated with new product development (including
clinical trials outcome and regulatory requirements/actions), competitive risks
to marketed products and availability of financing and other sources of capital,
as well as the risks discussed in the Company's filings with the Securities and
Exchange Commission. The Company is not under any obligation, and the Company
expressly disclaims any obligation, to update or alter any forward-looking
statements, whether as a result of new information, future events or otherwise.

     For More Information:
     Dr. Chau Cheng
     Associate Director, Investor Relations & Business Analysis
    (973) 605-8200, extension 123
     ccheng@immunomedics.com